Publication: 2803

Prophylactic Tetracycline Does Not Diminish the Severity of Epidermal Growth Factor Receptor (EGFR) Inhibitor Induced Rash: Results from the North Central Cancer Treatment Group (Supplementary N03CB)1
      QxMD      Google Scholar   
Citation:
Support Care Cancer vol 19 (10) 1601-1607
Year:
2011
Type:
Manuscript
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
CCP
Primary Committee:
Symptom Inter
Sec. Committees:
Health Outcomes    
Pharmas:
 
Grants:
U10 CA035267, U10 CA037417, K24 CA131099, N01 CA035431, U10 CA035269, CA-37404, CA-35090, CA-35195, U10 CA037404, U10 CA063848, U10 CA035195, CA-35103, CA-25224, CA-35113, U10 CA035101, U10 CA035113, CA-63848, U10 CA035415, CA-35415, U10 CA035431, CA-37417, CA-35269, CA-35101, U10 CA025224, U10 CA035090, CA-35267, CA-63849, U10 CA035103  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N03CB
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
Keywords:
tetracycline, rash, EGFR inhibitor, EGFR inhibitor-induced rash